We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Economic Burden among Commercially Insured Patients with Systemic Sclerosis in the United States.
- Authors
Zhou Zhou; Yanni Fan; Wenxi Tang; Xinyue Liu; Thomason, Darren; Zheng-Yi Zhou; Macaulay, Dendy; Fischer, Aryeh; Zhou, Zhou; Fan, Yanni; Tang, Wenxi; Liu, Xinyue; Zhou, Zheng-Yi
- Abstract
<bold>Objective: </bold>To quantify healthcare resource utilization (HRU), work loss, and annual direct and indirect healthcare costs among patients with systemic sclerosis (SSc) compared to matched controls in the United States.<bold>Methods: </bold>Data were obtained from a large US commercial claims database. Patients were ≥ 18 years old at the index date (first SSc diagnosis) and had ≥ 1 SSc diagnosis in the inpatient (IP) or emergency room (ER) setting, or ≥ 2 SSc diagnoses on 2 different dates in the outpatient (OP) setting between January 1, 2005, and March 31, 2015; continuous enrollment was required during the followup period (12 months after the index date). Individuals with no SSc diagnoses were matched 1:1 to patients with SSc. Wilcoxon signed-rank and McNemar tests were used for comparisons and regressions with generalized estimating equations for adjusted OR (aOR) and incidence rate ratios (IRR) between 2 cohorts.<bold>Results: </bold>There were 2192 pairs of patients with SSc and matched controls included (mean age 57.6 yrs; 84.3% female); of these, 233 were eligible for work loss/indirect cost analyses. Compared to matched controls, patients with SSc had significantly higher HRU and costs during the 1-year followup period, IP admissions (adjusted IRR = 2.4), IP hospitalization days (adjusted IRR = 3.1), ER visits (adjusted IRR = 2.0), OP visits (adjusted IRR = 2.3), and days of work loss (adjusted IRR = 2.6). The adjusted difference in annual direct and indirect costs was US$12,820 and $3103, respectively (all p < 0.0001).<bold>Conclusion: </bold>Patients with SSc had a high direct and indirect economic burden postdiagnosis.
- Publication
Journal of Rheumatology, 2019, Vol 46, Issue 8, p920
- ISSN
0315-162X
- Publication type
journal article
- DOI
10.3899/jrheum.180445